Nuvation Bio is a global oncology company developing small-molecule therapies targeting validated cancer pathways, founded by experienced drug developers with a track record in successful oncology programs. The company generates revenue through product sales of its marketed therapies, milestone and royalty payments from out-licensing partnerships in major markets including the U.S., China, Japan, and Europe, and upstream royalties owed to research-stage licensors. Nuvation combines expertise in medicinal chemistry and clinical development to design differentiated drug candidates addressing safety and efficacy limitations of competing therapies, including its proprietary drug-drug conjugate platform that fuses tissue-targeting molecules with anti-cancer payloads.